|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Autologous CD34^+ and CD133^+ stem cells transplantation in patients with end stage liver disease显示文摘AIM:To assess the utility of an autologous CD34 + and CD133 + stem cells infusion as a possible therapeutic modality in patients with end-stage liver diseases.METHODS:One hundred and forty patients with endstage liver diseases were randomized into two groups.Group 1,comprising 90 patients,received granulocyte colony stimulating factor for five days followed by autologous CD34 + and CD133 + stem cell infusion in the portal vein.Group 2,comprising 50 patients,received regular liver treatment only and served as a control group.RESULTS:Near normalization of liver enzymes and improvement in synthetic function were observed in 54.5% of the group 1 patients;13.6% of the patients showed stable states in the infused group.None of the patients in the control group showed improvement.No adverse effects were noted.CONCLUSION:Our data showed that a CD34 + and CD133 + stem cells infusion can be used as supportive treatment for end-stage liver disease with satisfactory tolerability. | Hosny Salama Abdel-Rahman N Zekri Abeer A Bahnassy Eman Medhat Hanan A Halim Ola S Ahmed Ghada Mohamed Sheren A Al Alim Ghada M Sherif | 2010 | World Journal of Gastroenterology2010，16，42： | 16 |
| 2 | Circulating tumor and cancer stem cells in hepatitis C virusassociated liver disease显示文摘AIM:To assess the role of circulating tumor cells(CTCs)and cancer stem cells(CSCs)in hepatitis C virus(HCV)-associated liver disease.METHODS:Blood and/or tissue samples were obtained from HCV(genotype 4)-associated hepatocellularcarcinoma patients(HCC;n=120),chronic hepatitis C patients(CH;n=30)and 33 normal control subjects(n=33).Serum levels of alpha-fetoprotein(AFP),alkaline phosphatase,and alanine and aspartate aminotransferases were measured.Cytokeratin 19(CK19)monoclonal antibody was used to enumerate CTCs,and CD133 and CD90 were used to enumerate CSCs by flow cytometry.The expression levels of the CSCs markers(CD133 and CD90)as well as telomerase,melanoma antigen encoding gene 1(MAGE1)and MAGE3 were assessed by RTPCR and quantitative real-time polymerase chain reactions.The number of CTCs and/or the expression levels of CK19,CD133,telomerase,MAGE1 and MAGE3 were correlated to the standard clinicopathologic prognostic factors and disease progression.RESULTS:Levels of AFP,alkaline phosphatase and aspartate aminotransferase were significantly different among the HCC,CH and control groups(P<0.001),whereas alanine aminotransferase differed significantly between patient(HCC and CH)and control groups(P<0.001).At the specified cutoff values determine by flow cytometry,CK19(49.8),CD90(400)and CD133(73)were significantly higher in the blood of HCC patients compared to those in the CH and control groups(P<0.001).On the other hand,CD133 at a 69.5 cutoff was significantly higher in the CH compared to the control group(P≤0.001).Telomerase,MAGE1 and MAGE3RNA were expressed in 55.71%,60.00%and 62.86%of the HCC patients,respectively,but were not detected in patients in the CH or control groups,which were statistically significant(Ps<0.001).The expression levels of telomerase,CD90,MAGE3,CD133 and CK19 were all significantly associated with high tumor grade and advanced stage in HCC patients(all P s<0.05).CONCLUSION:CTC counts and AFP,CK19,telomerase,and MAGE1/MAGE3 expression predict disease progression in patients with HCV,whereas telomerase,MAGE3,CD90,CD133 and CK19 are prognostic mark- | Abeer A Bahnassy Abdel-Rahman N Zekri Ahmed El-Bastawisy Amal Fawzy Marwa Shetta Nehal Hussein Dalia Omran Abdallah A S Ahmed Samir S El-Labbody | 2014 | World Journal of Gastroenterology2014，20，48： | 9 |
| 3 | Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions显示文摘AIM To assess the levels of different immune modulators in patients with hepatocellular carcinoma(HCC),in relation to other hepatic diseases.METHODS Eighty-eight patients were included in the current study and represented patients with HCC(20),liver cirrhosis(28) and chronic hepatitis(CH;25),and normal controls(NC;15).Peripheral blood was isolated for immunophenotyping of active myeloid dendritic cells(m DCs;CD1 c and CD40),mature inactive myeloid cells(CD1 c and HLA),active plasmacytoid cells(p DCs;CD303 and CD40),mature inactive p DCs(CD30 and HLA),active natural killer(NK) cells(CD56 and CD161),active NK cells(CD56 and CD314) and inactive NK cells(CD56 and CD158) was done by flow cytometry.Serum levels of interleukin(IL)-2,IL-10,IL-12,IL-1β,interferon(IFN)-α,IFN-γ and tumor necrosis factor(TNF)-αR2 were assessed by ELISA.RESULTS Active m DCs(CD1 C+/CD40+) and inactive m DCs(CD1 c+/HLA+) were significantly decreased in HCC patients in relation to NC(P < 0.001).CD40+ expression on active p DCs was decreased in HCC patients(P < 0.001),and its level was not significantly changed among other groups.Inactive p DCs(CD303+/HLA+),inactive NKs(CD56+/CD158+) and active NKs(CD56+/CD161+) were not statistically changed among the four groups studied;however,the latter was increased in CH(P < 0.05).NKG2 D was statistically decreased in HCC,CH and cirrhosis(P < 0.001),and it was not expressed in 63%(12/20) of HCC patients.There was significant decrease of IL-2,IFN-α and IFN-γ(P < 0.001),and a significant increase in IL-10,IL-1β,and TNF-αR2(P <0.01,P < 0.001 and P < 0.001;respectively) in HCC patients.There was inverted correlation between IL-12 and IL-1β in HCC(r =-0.565,P < 0.01),with a strong correlation between p DCs(CD303+/CD40+) and NKs(CD56+/CD161+;r = 0.512,P < 0.05) as well as inactive m DCs(CD1 c+/HLA+) and inactive NK cells(CD56+/CD158+;r = 0.945,P < 0.001).CONCLUSION NKG2 D,CD40,IL-2 and IL-10 are important modulators in the development and progression of HCC. | Abdel-Rahman N Zekri Somaya El Deeb Abeer A Bahnassy Abeer M Badr Mona S Abdellateif Gamal Esmat Hosny Salama Marwa Mohanad Ahmed Esam El-dien Shimaa Rabah Assmaa Abd Elkader | 2018 | World Journal of Gastroenterology2018，24，11： | 6 |
| 4 | Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression显示文摘AIM: To observe the imbalance between T helper cell Th1 and Th2 cytokines in several chronic hepatitis disease at different stages of disease progression.METHODS: We measured the cytokine levels of Th1 (IL-2 and IL-2R), Th2 (IL-10) and the pro-inflammatory cytokines (IL-6 and IL-6R and TNF and TNF-RⅠ and Ⅱ)by the ELISA technique in the sera of 33 hepatocellular carcinoma (HCC) patients and 20 chronic liver disease (CLD) patients. In addition, 20 asymptomatic hepatitis C virus carriers and 20 healthy subjects negative for hepatitis C virus(HCV) markers served as controls.RESULTS: Anti-HCV antibodies were found to be positive in 94% of HCC cases and 75% of CLD cases.On the other hand, HCV viremia was detected using RTPCR in 67% of HCC cases and 65% of CLD cases. HBsAg was positive in 9% of HCC cases and 30% of CLD cases.Also bilharzial-Ab was positive in 55% of HCC cases,65% of CLD cases and in 70% of asymptomatic carriers (ASC). HCC patients had significantly higher values of IL-2R, TNF-RⅡ (P<0.001), and TNF-RⅠ (P>0.05), but lower TNFα (P<0.001) and IL-6 (P = 0.032) in comparison to ASC. But, in comparison to non-cancer controls, HCC patients had higher values of IL-2R, IL-6R, TNF-RⅠ and TNF-RⅡ, but lower TNF-α (P<0.001). CLD patients had higher IL-2R, TNF-RⅠ, and TNF-RⅡ (P<0.001) than ASC. But, in comparison to non-cancer controls, CLD patients had higher values of IL-2R, TNF-RⅠ and TNF-RⅡ, but lower TNF-α (P<0.001). IL-10 was higher (though not significantly) in HCC and CLD patients than in symptomatic carriers and non-cancer controls.CONCLUSION: Liver disease progression from CLD to HCC due to HCV genotype-4 infection is associated with an imbalance between Th1 and Th2 cytokines. IL-2R,TNF-RⅠ, and TNF-RⅡ could be used as potential markers. | Abdel-Rahman N Zekri Mohammed S El-Din Ashour Ahmed Hassan Hanaa M Alam El-Din Amal MR El-Shehaby Maha A Abu-Shady | 2005 | World Journal of Gastroenterology2005，11，42： | 4 |
| 5 | Markers of bone turnover for the management of patients with bone metastases from prostate cancer显示文摘 | GARNERO P BUCHS N ZEKRI J | 2000 | Br J Cancer2000，82，4： | 1 |
| 6 | Markers of bone turnover for the management of patients with bone metastases from prostate cancer显示文摘 | Buchs N Zekri J | 2000 | Br J Cancer2000，82，4： | 1 |
| 7 | Perivascular epithelioid cell neoplasms: a systematic review of prog- nostic factors显示文摘 | Zekry N Rettenmaier MA Abaid LN | 2009 | J Minim Invasive Gynecol2009，16，5： | 1 |
| 8 | Real-time reverse transcriptasepolymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green Ⅰ 显示文摘 | Yin J L Shackel N A Zekry A | 2001 | Immunol Cell Biol2001，79，3： | 1 |
| 9 | Trugenesequencing versus INNO-LiPA for subtyping ofHCV genotype 4显示文摘 | Zekri A R N El-Din H M A Bahnassy A A | | 0，，： | 1 |
| 10 | The skeletal metastatic complications of renal cell carcinoma显示文摘 | Zekri J Ahmed N Coleman RE | 2001 | Int J Oncol2001，19，2： | 1 |
| 11 | Markers of bone turnover for the management of patients with bone metastases from prostate cancer显示文摘 | Garnero P Buchs N Zekri J | 2000 | BrJ Cancer2000，82，4： | 1 |
| 12 | Markers of bone turnover for the nanagement of patients with bone metastases from prostate cancer显示文摘 | Garnero P Buchs N Zekri J | 2000 | Br J Cancer2000，82，4： | 1 |
| 13 | Real-time reverse transcriptase polymerase chain reaction (RT- PCT) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green l显示文摘 | Yin J L Shackel N A Zekry A | 2001 | Immunol Cell Biol2001，79，3： | 1 |
| 14 | Real-time reverse transeriPtase Polyerase chain reaetion (RT-PCR) for measure- ment of cytokine and growth factor mRNA expression with flu orogenic Probes or SYBR Green I 显示文摘 | YIN J L SHACKEL N A ZEKRY A | 2001 | Immunol Cell Biol2001，79，3： | 1 |
| 15 | Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorescent probes or SYBR Green Ⅰ显示文摘 | Yin J L Shackel N A Zekry A | 2001 | Immunol Cell Biol2001，79，3： | 1 |
| 16 | Real-time reverse transeriptase polymerase chain reaction (RT-PCR)for measurement of eytokine and growth factor mRNA Expression with fluorescent Probes or SYBR Green I显示文摘 | YIN J L SHACKEL N A ZEKRY A | 2001 | Immunol Cell Biol2001，79，3： | 1 |
| 17 | Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green Ⅰ显示文摘 | Yin J L Shackel N A Zekry A | 2001 | Immunol Cell Biol2001，79，3： | 1 |
| 18 | Markers of bone turnover for the management of patients with bone metastases from prostate cancer显示文摘 | Garnero P Buchs N Zekri J | 2000 | Br J Cancer2000，82，： | 1 |
| 19 | Exemestane in metastatic breast cancer: Effective therapy after third-generation nonsteroidal aromatase inhibitor failure显示文摘 | Steele N Zekri J Coleman R | 2006 | The Breast2006，15，3： | 1 |
| 20 | Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factorm RNA expression with fluorogenic probes or SYBR Green Ⅰ 显示文摘 | Yin J L Shaekel N A Zekry A | 2001 | Immunology and Cell Biology2001，79，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员